Spots Global Cancer Trial Database for Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)
Official Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
Study ID: NCT03867097
Study Description
Brief Summary: This is a Phase 2, multicenter, double-blind, randomized, placebo-controlled study to evaluate the effect of iloprost on the symptomatic relief of Raynaud's Phenomenon attacks in subjects with symptomatic Raynaud's Phenomenon secondary to Systemic Sclerosis.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Arizona Arthritis & Rheumatology Research, PLLC, Phoenix, Arizona, United States
Pacific Arthritis Care Center of Los Angeles, Los Angeles, California, United States
Stanford University Medical Center, Palo Alto, California, United States
University of California San Francisco, San Francisco, California, United States
Georgetown University Medical Center - Department of Rheumatology, Washington, District of Columbia, United States
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
University of Michigan, Ann Arbor, Michigan, United States
Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
Hospital for Special Surgery, New York, New York, United States
Columbia University Medical Center, New York, New York, United States
Cleveland Clinic, Cleveland, Ohio, United States
The University of Toledo Medical Center (UTMC) - Ruppert Health Center, Toledo, Ohio, United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics, Houston, Texas, United States
Virginia Mason Medical Center, Seattle, Washington, United States
Arthritis Northwest Rheumatology PLLC, Spokane, Washington, United States
Contact Details
Name: Wade Benton, Pharm D
Affiliation: Civibio Pharma, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
